267 related articles for article (PubMed ID: 11895895)
41. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
[TBL] [Abstract][Full Text] [Related]
42. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
44. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
45. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
46. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
[TBL] [Abstract][Full Text] [Related]
47. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
48. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
[TBL] [Abstract][Full Text] [Related]
50. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
51. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
[TBL] [Abstract][Full Text] [Related]
52. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
53. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
54. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
55. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
Waters JS; Webb A; Cunningham D; Clarke PA; Raynaud F; di Stefano F; Cotter FE
J Clin Oncol; 2000 May; 18(9):1812-23. PubMed ID: 10784621
[TBL] [Abstract][Full Text] [Related]
56. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
57. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.
van de Donk NW; de Weerdt O; Veth G; Eurelings M; van Stralen E; Frankel SR; Hagenbeek A; Bloem AC; Lokhorst HM
Leukemia; 2004 Jun; 18(6):1078-84. PubMed ID: 15085157
[TBL] [Abstract][Full Text] [Related]
58. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
59. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
Rabinovich-Guilatt L; Elgart A; Erisson L; Willsie SK; Tessler S; Barnett-Griness O; Pande A; Spiegelstein O
Br J Clin Pharmacol; 2015 Sep; 80(3):436-45. PubMed ID: 25782535
[TBL] [Abstract][Full Text] [Related]
60. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Marcucci G; Byrd JC; Dai G; Klisovic MI; Kourlas PJ; Young DC; Cataland SR; Fisher DB; Lucas D; Chan KK; Porcu P; Lin ZP; Farag SF; Frankel SR; Zwiebel JA; Kraut EH; Balcerzak SP; Bloomfield CD; Grever MR; Caligiuri MA
Blood; 2003 Jan; 101(2):425-32. PubMed ID: 12393493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
